Announcement PDF 1 1 Resonance Health Andrew Harrison, CEO Benjamin Carruthers, CFO Half Year Results FY26 2 Highlights ü 1H FY26 Revenue up 53% or $2.8M to $8.0M from 1H FY25 ü 1H FY26 Normalised EBITDA of $1.6M at 20% operating margin ü Profit after tax of $1.5 million (1H FY25: $1.0 million loss) ü Positive operating cashflow ü Major global pharma clinical trial execution progressing as planned ü TrialsWest clinic network expansion progressing ahead of expectations ü SaMD order and bid (but not awarded) pipeline now above $10 million ü New Non-Invasive Liver Fibrosis medical device extended-proof-of- concept-trial (EPoC) completed subject enrolment ü New “Bridge” technology that automates and simplifies customer interaction has completed testing and validation with first customer deployment underway 3 Significant revenue growth and diversification with rapid scaling across 3 businesses… FY23 FY26 Total Revenue $4.4M Total Revenue Guidance ~$17M ü FY23–FY26 strong revenue growth (~45% CAGR) ü Profitable ~$2M EBITDA ü Diversified revenue ü Customer, clinical, and technical synergies Rapid scaling across 3 businesses Full Year FY26 Guidance 4 We continue to significantly expand our addressable global market… New Imaging Endpoints for Metabolic & Obesity VAT, SAT, MRE 2023 MRI Liver Iron Measurement market ~ $200M + liver fat market ~$300m + + obesity and liver fibrosis >$500m + CRO and Investigator site services ~$70b # Data compiled from internal company market research 5 The strategy of getting a greater “share of wallet” expands on 3 vector's, more therapeutic areas, more services to each customer, and more customers through organic (SaMD) or acquisitive (buy expertise & footprint) growth. Oncology/Hematology, 28% Neurology, 8% Infectious Disease (Therapeutic ), 8% Endocrin ology, 6% Rheumatology, 5% Cardiovascular, 5% Dermatology, 5% Infectious Disease (Immunizatio… Respiratory, 4% Ophthalmol ogy, 4% Psychiat ry, 3% Hematol ogy, 3% Gast roint es… Repr oduc tiv… Hepa tolog y,… Other, 10% % $ SPENDING IN GLOBAL CLINICAL TRIALS BY THERAPEUTIC AREA More sites – Geographic (Australia then overseas) More phases – Later stage to Phase 1 More devices and imaging endpoints More services provided in-house Other services More Services More Therapeutic Areas More Customers # Data compiled from internal company market research 6 Therapeutic Area Services Work Won Opportunities Haematology First Liver / Spleen Iron, then Site services - TrialsWest Haematology First Liver / Spleen Iron, then central reading & image storage Metabolic First CRO, then Site services – TrialsWest, & Liver fat & Stiffness Obesity First Liver fat & VAT / SAT, then CRO & Site Services ENT First site services, then CRO Services Australian global pharma US global pharma Top 10 Indian global pharma US Biotech Growth strategy continues to bear early fruit… Oncology CRO & Imaging Services US Biotech Top 10 Indian global pharma 7 Australian Clinical Trial Market Global Clinical Trial Market Key Drivers - Australia Key Drivers - Globally ü Approvals and regulatory system ü Public private health system ü Multi-cultural population ü Population receptive to testing / participation ü R&D Tax incentives ü Increasing rapidity of technological breakthroughs ü Shortening development timeframes ü Increase in outsourcing of trials ü Increase in efficiency of non-hospital trials Strong Tailwinds 8 While oncology dominates the global trial landscape, there is rapid growth in other therapeutic areas… # Data compiled from internal company market research 9 In the metabolic diseases space rapid growth is being driven by GLP-1-like drugs # Data compiled from internal company market research 10 Resonance’s deep expertise in liver and related metabolic / obesity areas meets a significant opportunity… # Data compiled from internal company market research 11 Growth with financial discipline… Entrenched profitability üBuild revenue base üDisciplined cost control üBusiness transformation providing strong financial base with significant growth potential Generate strong FCF üOperating cash flow positive üLow sustaining capex üAccretive expansion capex & acquisitions Target EBITDA Margin Range ~ 25% üEstablished overhead base that can be leveraged üRevenue growth across three business segments, looking to drive margin uplift at full revenue scale üGreater share of wallet reduces customer acquisition costs and increases margin capture / customer / project Responsible growth üConservative gearing metrics - target Net Debt EBITDA < 2x (long term ~ 1.5x) üMaintain a strong balance sheet – financial strength and greater flexibility to pursue attractive opportunities üProperly support and embed new business streams and acquisitions 12 ü 53% revenue growth on pcp ü 20% normalised EBITDA margin, significant operating leverage driving margin accretion in future growth2 ü Significant increase in NPAT to $1.5M Profit & Loss Summary1 1HFY26 1HFY25 %Change Revenue $M 8.0 5.2 +53% Normalised EBITDA 1.6 (0.8) Normalised EBITDA Margin 20% -14% Statutory NPBT 0.9 (1.5) Statutory NPAT 1.5 (1.0) 1Abridged summary prepared for comparative purposes, refer to Annual Report for Statutory Accounts 2Normalised EBITDA = Statutory net profit – income tax – depreciation – amortisation – finance costs – share based payments 1HFY26 PROFIT & LOSS 13 1HFY26 BALANCE SHEET ü Strong net cash position $2.7M ü $2.7M debt facility Balance Sheet Summary1 $M 1HFY26 1HFY25 Assets Cash & Equivalents 2.7 3.0 Trade debtors and other receivables 3.5 3.5 Intangibles 9.4 9.5 PPE and other assets 2.3 1.9 Liabilities Trade and other payables (1.6) (1.3) Borrowings (2.7) (2.9) Revenue received in advance (0.9) (3.2) Other liabilities (1.9) (1.2) Net Assets 10.9 9.4 1 Abridged summary prepared for comparative purposes, refer to Annual Report for Statutory Accounts 14 Business Outlook & Guidance Resonance enters 2H FY26 with: ü Continued delivery under global major pharmaceutical agreements ü Record SaMD forward orders and bid-tender pipeline ü Expanding and increasingly profitable TrialsWest operations ü Near-term milestones in fibrosis SaMD development and workflow automation ü Previously stated guidance of full year FY26 Revenue of $17M and EBITDA of $2M is maintained. 15 Disclaimer Forward Looking Statements This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this presentation may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health’s products and services. These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law. This presentation does not constitute or form part of an offer of securities or a solicitation of invitation to buy or apply for securities, nor may it or any part of it form the basis of or be relied on in any connection with any contract or commitment. The information in this presentation does not take into account the objectives, financial situation or individual needs of any person. Nothing contained in this presentation constitutes investment, legal, tax, or other advice. Potential investors should make their own decisions whether to invest in Resonance Health shares based on their own enquiries and are advised to seek appropriate independent advice. This presentation does not, and does not purport to, contain all the information prospective investors in Resonance Health would desire or require in reaching an investment decision. To the maximum extent possible by law, none of Resonance Health, their officers, directors, employees, associates, or agents, nor any other person’s accepts any liability for any loss, claim, damages, costs or expenses of whatever nature (whether or not foreseeable), including, without limitation, any liability arising from fault or negligence on the part of any of them or any other person, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it or any error or omissions in it. 16 resonance-health-ltd/